Third Harmonic Bio
THRD
THRD was delisted on the 30th of July, 2025.
50 hedge funds and large institutions have $153M invested in Third Harmonic Bio in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 18 closing their positions.
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
25% more funds holding
Funds holding: 40 → 50 (+10)
3.84% less ownership
Funds ownership: 91.67% → 87.83% (-3.8%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
77% less capital invested
Capital invested by funds: $673M → $153M (-$520M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$33.7M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$28.4M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$14.5M |
| 4 |
BlackRock
New York
|
+$12.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$49.2M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$18.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.9M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$13.8M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$3.79M |
THRD Hedge Fund Activity: Q4 2022 in Review
50 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q4 2022, worth a combined $153M — down 77% from $673M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new THRD positions and 18 closed out — a net gain of 10 holders — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $33.7M. The largest seller was RA Capital Management, cutting an estimated $49.2M.
- 50 institutional investors held Third Harmonic Bio (THRD) as of Q4 2022, up from 40 in Q3 2022.
- Funds reported $153M of Third Harmonic Bio stock for Q4 2022, down 77% quarter-over-quarter.
- 28 funds opened new Third Harmonic Bio positions in Q4 2022 and 18 closed out, a net change of +10 holders.
- The largest Third Harmonic Bio buyer in Q4 2022 was Stonepine Capital Management, an estimated $33.7M added.
- The largest Third Harmonic Bio seller in Q4 2022 was RA Capital Management, an estimated $49.2M sold.
Based on aggregated 13F filings for Q4 2022.